Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 521

1.

Impaired expression of innate immunity-related genes in IgG4-related disease (IgG4-RD): A possible mechanism in the pathogenesis of IgG4-RD.

Nakamura T, Satoh-Nakamura T, Nakajima A, Kawanami T, Sakai T, Fujita Y, Iwao H, Miki M, Masaki Y, Okazaki T, Ishigaki Y, Kawano M, Yamada K, Matsui S, Saeki T, Kamisawa T, Yamamoto M, Hamano H, Origuchi T, Hirata S, Yoshiya T, Tsuboi H, Sumida T, Okazaki K, Tanaka M, Chiba T, Mimori T, Umehara H.

Mod Rheumatol. 2019 May 22:1-17. doi: 10.1080/14397595.2019.1621475. [Epub ahead of print]

PMID:
31116057
2.

Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis.

Ishigooka N, Fujii T, Abe H, Murakami K, Nakashima R, Hashimoto M, Yoshifuji H, Tanaka M, Ito H, Ohmura K, Morita S, Mimori T.

Mod Rheumatol. 2019 Jun 13:1-8. doi: 10.1080/14397595.2019.1621439. [Epub ahead of print]

PMID:
31116051
3.

The development of quality indicators for systemic lupus erythematosus using electronic health data: a modified RAND appropriateness method.

Yajima N, Tsujimoto Y, Fukuma S, Sada KE, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura-Ogasawara M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, Atsumi T.

Mod Rheumatol. 2019 May 21:1-15. doi: 10.1080/14397595.2019.1621419. [Epub ahead of print]

PMID:
31111758
4.

Evaluation of risk factors for atherosclerosis using carotid ultrasonography in Japanese patients with rheumatoid arthritis.

Yamamoto H, Nakajima T, Kawahara R, Nakabo S, Hashimoto M, Yamamoto W, Masuda I, Ito H, Mimori T, Fujii Y.

Int J Rheum Dis. 2019 May 17. doi: 10.1111/1756-185X.13591. [Epub ahead of print]

PMID:
31099177
5.

Strain-Specific Manifestation of Lupus-like Systemic Autoimmunity Caused by Zap70 Mutation.

Matsuo T, Hashimoto M, Sakaguchi S, Sakaguchi N, Ito Y, Hikida M, Tsuruyama T, Sakai K, Yokoi H, Shirakashi M, Tanaka M, Ito H, Yoshifuji H, Ohmura K, Fujii T, Mimori T.

J Immunol. 2019 Jun 1;202(11):3161-3172. doi: 10.4049/jimmunol.1801159. Epub 2019 Apr 24.

PMID:
31019063
6.

Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients.

Kang EH, Go DJ, Mimori T, Lee SJ, Kwon HM, Park JW, Park MH, Song EY, Ha YJ, Lee EY, Lee YJ, Lee EB, Song YW.

Semin Arthritis Rheum. 2019 Mar 9. pii: S0049-0172(18)30753-4. doi: 10.1016/j.semarthrit.2019.03.005. [Epub ahead of print]

PMID:
30952422
7.

Publishing Immunological Medicine-changing from Japanese Journal of Clinical Immunology.

Mimori T.

Immunol Med. 2018 Mar;41(1):1. doi: 10.1080/09114300.2018.1451588. Epub 2018 Apr 4. No abstract available.

PMID:
30938252
8.

Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective.

Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, Garcia de la Torre I, Herold M, Klotz W, Cruvinel WM, Mimori T, von Muhlen C, Satoh M, Chan EK.

Ann Rheum Dis. 2019 Jul;78(7):879-889. doi: 10.1136/annrheumdis-2018-214436. Epub 2019 Mar 12.

9.

Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease.

Nakatsuka Y, Handa T, Nakashima R, Tanizawa K, Kubo T, Murase Y, Sokai A, Ikezoe K, Hosono Y, Watanabe K, Tokuda S, Uno K, Yoshizawa A, Tsuruyama T, Uozumi R, Nagai S, Hatta K, Taguchi Y, Mishima M, Chin K, Mimori T, Hirai T.

Rheumatology (Oxford). 2019 Mar 8. pii: kez065. doi: 10.1093/rheumatology/kez065. [Epub ahead of print]

PMID:
30851107
10.

Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.

Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, Yamamoto W, Mimori T, Terao C.

Semin Arthritis Rheum. 2019 Feb 10. pii: S0049-0172(18)30436-0. doi: 10.1016/j.semarthrit.2019.02.003. [Epub ahead of print]

PMID:
30803720
11.

Activated neutrophil carbamylates albumin via the release of myeloperoxidase and reactive oxygen species regardless of NETosis.

Nakabo S, Ohmura K, Akizuki S, Murakami K, Nakashima R, Hashimoto M, Yoshifuji H, Tanaka M, Mimori T.

Mod Rheumatol. 2019 Feb 21:1-5. doi: 10.1080/14397595.2019.1583819. [Epub ahead of print]

PMID:
30789095
12.

Maternity Log study: a longitudinal lifelog monitoring and multiomics analysis for the early prediction of complicated pregnancy.

Sugawara J, Ochi D, Yamashita R, Yamauchi T, Saigusa D, Wagata M, Obara T, Ishikuro M, Tsunemoto Y, Harada Y, Shibata T, Mimori T, Kawashima J, Katsuoka F, Igarashi-Takai T, Ogishima S, Metoki H, Hashizume H, Fuse N, Minegishi N, Koshiba S, Tanabe O, Kuriyama S, Kinoshita K, Kure S, Yaegashi N, Yamamoto M, Hiyama S, Nagasaki M.

BMJ Open. 2019 Feb 19;9(2):e025939. doi: 10.1136/bmjopen-2018-025939.

13.

Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies.

Espinosa-Ortega F, Holmqvist M, Alexanderson H, Storfors H, Mimori T, Lundberg IE, Rönnelid J.

Ann Rheum Dis. 2019 Jun;78(6):858-860. doi: 10.1136/annrheumdis-2018-214690. Epub 2019 Feb 13. No abstract available.

PMID:
30760469
14.

Utility of osteopontin in cerebrospinal fluid as a diagnostic marker for neuropsychiatric systemic lupus erythematosus.

Kitagori K, Yoshifuji H, Oku T, Ayaki T, Kuzuya A, Nakajima T, Akizuki S, Nakashima R, Murakami K, Ohmura K, Hirayama Y, Takahashi R, Mimori T.

Lupus. 2019 Mar;28(3):414-422. doi: 10.1177/0961203319828818. Epub 2019 Feb 11.

PMID:
30744522
15.

PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes.

Akizuki S, Ishigaki K, Kochi Y, Law SM, Matsuo K, Ohmura K, Suzuki A, Nakayama M, Iizuka Y, Koseki H, Ohara O, Hirata J, Kamatani Y, Matsuda F, Sumida T, Yamamoto K, Okada Y, Mimori T, Terao C.

Ann Rheum Dis. 2019 Apr;78(4):509-518. doi: 10.1136/annrheumdis-2018-214116. Epub 2019 Jan 24.

PMID:
30679154
16.

IgG4-related disease - A new disease entity developed in the twenty-first century.

Mimori T.

Mod Rheumatol. 2019 Mar;29(2):213. doi: 10.1080/14397595.2019.1573789. Epub 2019 Feb 19. No abstract available.

PMID:
30676824
17.

Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.

Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, Karayama M, Furuhashi K, Enomoto N, Inui N, Nakamura Y, Mimori T, Suda T.

J Rheumatol. 2019 May;46(5):509-517. doi: 10.3899/jrheum.180778. Epub 2019 Jan 15.

PMID:
30647164
18.

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists.

Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T.

Mod Rheumatol. 2019 Jan;29(1):1-19. doi: 10.1080/14397595.2018.1521185. Epub 2018 Dec 19.

PMID:
30565491
19.

Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists.

Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, Kawaguchi Y, Jinnin M, Muro Y, Ishihara S, Tomimitsu H, Ohta A, Sumida T.

J Dermatol. 2019 Jan;46(1):e1-e18. doi: 10.1111/1346-8138.14604. Epub 2018 Dec 18.

PMID:
30562845
20.

Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis.

Terao C, Yoshifuji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, Kirino Y, Matsuo K, Origuchi T, Shimizu M, Maejima Y, Amiya E, Tamura N, Kawaguchi T, Takahashi M, Setoh K, Ohmura K, Watanabe R, Horita T, Atsumi T, Matsukura M, Miyata T, Kochi Y, Suda T, Tanemoto K, Meguro A, Okada Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Kuwana M, Mizuki N, Tabara Y, Ueda A, Komuro I, Kimura A, Isobe M, Mimori T, Matsuda F.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13045-13050. doi: 10.1073/pnas.1808850115. Epub 2018 Nov 29.

21.

Genome analyses for the Tohoku Medical Megabank Project towards establishment of personalized healthcare.

Yasuda J, Kinoshita K, Katsuoka F, Danjoh I, Sakurai-Yageta M, Motoike IN, Kuroki Y, Saito S, Kojima K, Shirota M, Saigusa D, Otsuki A, Kawashima J, Yamaguchi-Kabata Y, Tadaka S, Aoki Y, Mimori T, Kumada K, Inoue J, Makino S, Kuriki M, Fuse N, Koshiba S, Tanabe O, Nagasaki M, Tamiya G, Shimizu R, Takai-Igarashi T, Ogishima S, Hozawa A, Kuriyama S, Sugawara J, Tsuboi A, Kiyomoto H, Ishii T, Tomita H, Minegishi N, Suzuki Y, Suzuki K, Kawame H, Tanaka H, Taki Y, Yaegashi N, Kure S, Nagami F; Tohoku Medical Megabank Project Study Group, Kosaki K, Sutoh Y, Hachiya T, Shimizu A, Sasaki M, Yamamoto M.

J Biochem. 2019 Feb 1;165(2):139-158. doi: 10.1093/jb/mvy096.

PMID:
30452759
22.

Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.

Nishioka A, Tsunoda S, Abe T, Yoshikawa T, Takata M, Kitano M, Matsui K, Nakashima R, Hosono Y, Ohmura K, Mimori T, Sano H.

Mod Rheumatol. 2018 Nov 19:1-7. doi: 10.1080/14397595.2018.1548918. [Epub ahead of print]

PMID:
30449228
23.

Autoantibodies to killer cell immunoglobulin-like receptor 3DL1 in patients with systemic lupus erythematosus.

Doi A, Kano S, Asano M, Takahashi Y, Mimori T, Mimori A, Kaneko H.

Clin Exp Immunol. 2019 Mar;195(3):358-363. doi: 10.1111/cei.13235. Epub 2018 Dec 14.

PMID:
30421793
24.

Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort.

Murata K, Ito H, Hashimoto M, Nishitani K, Murakami K, Tanaka M, Yamamoto W, Mimori T, Matsuda S.

Int J Rheum Dis. 2018 Nov 11. doi: 10.1111/1756-185X.13428. [Epub ahead of print]

PMID:
30415498
25.

Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis.

Nakagawa S, Nakaishi M, Hashimoto M, Ito H, Yamamoto W, Nakashima R, Tanaka M, Fujii T, Omura T, Imai S, Nakagawa T, Yonezawa A, Imai H, Mimori T, Matsubara K.

PLoS One. 2018 Nov 2;13(11):e0206943. doi: 10.1371/journal.pone.0206943. eCollection 2018.

26.

Effect of physical state on pain mediated through emotional health in rheumatoid arthritis.

Nakagami Y, Sugihara G, Takei N, Fujii T, Hashimoto M, Murakami K, Furu M, Ito H, Uda M, Torii M, Nin K, Murai T, Mimori T.

Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23779. [Epub ahead of print]

PMID:
30295427
27.

Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study.

Matsuo T, Hashimoto M, Ito I, Kubo T, Uozumi R, Furu M, Ito H, Fujii T, Tanaka M, Terao C, Kono H, Mori M, Hamaguchi M, Yamamoto W, Ohmura K, Morita S, Mimori T.

Scand J Rheumatol. 2019 Mar;48(2):87-94. doi: 10.1080/03009742.2018.1477989. Epub 2018 Sep 30.

PMID:
30269670
28.

Significant joint-destructive association of HLA-DRB1*04:05 independent of DAS28 in rheumatoid arthritis.

Tsuji H, Ikari K, Ohmura K, Yano K, Furu M, Hashimoto M, Ito H, Fujii T, Yamamoto W, Taniguchi A, Yamanaka H, Mimori T, Terao C.

Ann Rheum Dis. 2019 Feb;78(2):284-286. doi: 10.1136/annrheumdis-2018-214022. Epub 2018 Sep 19. No abstract available.

PMID:
30232193
29.

Anti-PL-12 antibody-positive antisynthetase syndrome with recurrent digital ulcers.

Miyagawa F, Azukizawa H, Mimori T, Asada H.

J Dermatol. 2019 Apr;46(4):e143-e145. doi: 10.1111/1346-8138.14661. Epub 2018 Sep 19. No abstract available.

PMID:
30230582
30.

Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance.

Harigai M, Ishiguro N, Inokuma S, Mimori T, Ryu J, Takei S, Takeuchi T, Tanaka Y, Takasaki Y, Yamanaka H, Yoshizawa Y, Chinen I, Nakao T, Koike T.

Mod Rheumatol. 2018 Oct 25:1-9. doi: 10.1080/14397595.2018.1524998. [Epub ahead of print]

PMID:
30217117
31.

Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders.

Murakami K, Mimori T.

Intern Med. 2019 Jan 1;58(1):5-14. doi: 10.2169/internalmedicine.1423-18. Epub 2018 Aug 24. Review.

32.

Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid Arthritis.

Yoshiji S, Takahashi K, Sawada K, Mishima M, Eso Y, Morita M, Takai A, Marusawa H, Ueda Y, Mimori T, Seno H.

Intern Med. 2019 Jan 1;58(1):67-71. doi: 10.2169/internalmedicine.0843-18. Epub 2018 Aug 24.

33.

Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis.

Torii M, Hashimoto M, Hanai A, Fujii T, Furu M, Ito H, Uozumi R, Hamaguchi M, Terao C, Yamamoto W, Uda M, Nin K, Morita S, Arai H, Mimori T.

Mod Rheumatol. 2018 Sep 11:1-7. doi: 10.1080/14397595.2018.1510565. [Epub ahead of print]

PMID:
30092163
34.

Laminin 511 is a target antigen in autoimmune pancreatitis.

Shiokawa M, Kodama Y, Sekiguchi K, Kuwada T, Tomono T, Kuriyama K, Yamazaki H, Morita T, Marui S, Sogabe Y, Kakiuchi N, Matsumori T, Mima A, Nishikawa Y, Ueda T, Tsuda M, Yamauchi Y, Sakuma Y, Maruno T, Uza N, Tsuruyama T, Mimori T, Seno H, Chiba T.

Sci Transl Med. 2018 Aug 8;10(453). pii: eaaq0997. doi: 10.1126/scitranslmed.aaq0997.

PMID:
30089633
35.

Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.

Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, Ohnishi A, Akashi K, Yoshida S, Nagai K, Son Y, Amuro H, Hirano T, Ebina K, Uozumi R, Ito H, Tanaka M, Ohmura K, Fujii T, Mimori T.

Arthritis Res Ther. 2018 Aug 3;20(1):165. doi: 10.1186/s13075-018-1673-1.

36.

Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naïve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan.

Tanaka Y, Mimori T, Yamanaka H, Nakajima R, Morita K, Kimura J, Takeuchi T.

Mod Rheumatol. 2018 Sep 11:1-9. doi: 10.1080/14397595.2018.1500979. [Epub ahead of print]

PMID:
30009649
37.

Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.

Shirakashi M, Yoshifuji H, Kodama Y, Chiba T, Yamamoto M, Takahashi H, Uchida K, Okazaki K, Ito T, Kawa S, Yamada K, Kawano M, Hirata S, Tanaka Y, Moriyama M, Nakamura S, Kamisawa T, Matsui S, Tsuboi H, Sumida T, Shibata M, Goto H, Sato Y, Yoshino T, Mimori T.

Sci Rep. 2018 Jul 6;8(1):10262. doi: 10.1038/s41598-018-28405-x.

38.

Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study.

Yoshida T, Hashimoto M, Kawahara R, Yamamoto H, Tanaka M, Ito H, Masuda I, Hosoda K, Yamamoto W, Uozumi R, Morita S, Fujii Y, Mimori T, Nin K.

Rheumatol Int. 2018 Sep;38(9):1679-1689. doi: 10.1007/s00296-018-4095-0. Epub 2018 Jul 4.

39.

Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.

Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, Kawakami A.

Medicine (Baltimore). 2018 Jun;97(26):e11024. doi: 10.1097/MD.0000000000011024.

40.

Predictive factors for structural remission using abatacept: Results from the ABROAD study.

Murakami K, Sekiguchi M, Hirata S, Fujii T, Matsui K, Morita S, Ohmura K, Kawahito Y, Nishimoto N, Mimori T, Sano H; ABROAD study investigators.

Mod Rheumatol. 2019 May;29(3):406-412. doi: 10.1080/14397595.2018.1482609. Epub 2018 Jun 27.

PMID:
29807445
41.

[Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The Pathophysiology in Rheumatoid Arthritis.]

Murakami K, Mimori T.

Clin Calcium. 2018;28(5):595-600. doi: CliCa1805595600. Japanese.

PMID:
29731451
42.

Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis.

Oba K, Horie N, Sato N, Saito K, Takeuchi T, Mimori T, Miyasaka N, Koike T, Tanaka Y.

Contemp Clin Trials Commun. 2017 Aug 17;8:49-54. doi: 10.1016/j.conctc.2017.08.007. eCollection 2017 Dec.

43.

Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.

Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Yamamoto K, Ikeuchi S, Kushimoto S, Koike T.

Mod Rheumatol. 2019 Mar;29(2):314-323. doi: 10.1080/14397595.2018.1460230. Epub 2018 Apr 27.

PMID:
29611761
44.

Factors affecting walking ability in female patients with rheumatoid arthritis.

Morita Y, Ito H, Torii M, Hanai A, Furu M, Hashimoto M, Tanaka M, Azukizawa M, Arai H, Mimori T, Matsuda S.

PLoS One. 2018 Mar 27;13(3):e0195059. doi: 10.1371/journal.pone.0195059. eCollection 2018.

45.

Glucocorticoid receptor expression in resident and hematopoietic cells in IgG4-related disease.

Iguchi T, Takaori K, Mii A, Sato Y, Suzuki Y, Yoshifuji H, Seno H, Ogawa O, Omori K, Bessho K, Kondo S, Yoshizaki T, Nakashima H, Saito T, Mimori T, Haga H, Kawano M, Yanagita M.

Mod Pathol. 2018 Jun;31(6):890-899. doi: 10.1038/s41379-018-0036-4. Epub 2018 Feb 12.

46.

HLA-DRB1 Analysis Identified a Genetically Unique Subset within Rheumatoid Arthritis and Distinct Genetic Background of Rheumatoid Factor Levels from Anticyclic Citrullinated Peptide Antibodies.

Hiwa R, Ikari K, Ohmura K, Nakabo S, Matsuo K, Saji H, Yurugi K, Miura Y, Maekawa T, Taniguchi A, Yamanaka H, Matsuda F, Mimori T, Terao C.

J Rheumatol. 2018 Apr;45(4):470-480. doi: 10.3899/jrheum.170363. Epub 2018 Feb 1.

PMID:
29419463
47.

Clinical practice guideline for Sjögren's syndrome 2017.

Sumida T, Azuma N, Moriyama M, Takahashi H, Asashima H, Honda F, Abe S, Ono Y, Hirota T, Hirata S, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Sano H, Ogawa Y, Tsubota K, Ryo K, Saito I, Tanaka A, Nakamura S, Takamura E, Tanaka M, Suzuki K, Takeuchi T, Yamakawa N, Mimori T, Ohta A, Nishiyama S, Yoshihara T, Suzuki Y, Kawano M, Tomiita M, Tsuboi H.

Mod Rheumatol. 2018 May;28(3):383-408. doi: 10.1080/14397595.2018.1438093. Epub 2018 Mar 13. Review.

PMID:
29409370
48.

[A case of anti-PL-7 antibody positive polymyositis with thrombotic microangiopathy].

Tamura M, Kitano M, Azuma K, Tsuboi K, Abe T, Ogita C, Yokoyama Y, Furukawa T, Yoshikawa T, Saito A, Nishioka A, Sekiguchi M, Azuma N, Tsunoda S, Hosono Y, Nakashima R, Ohmura K, Matsui K, Mimori T, Sano H.

Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(6):450-455. doi: 10.2177/jsci.40.450. Japanese.

49.

Construction of full-length Japanese reference panel of class I HLA genes with single-molecule, real-time sequencing.

Mimori T, Yasuda J, Kuroki Y, Shibata TF, Katsuoka F, Saito S, Nariai N, Ono A, Nakai-Inagaki N, Misawa K, Tateno K, Kawai Y, Fuse N, Hozawa A, Kuriyama S, Sugawara J, Minegishi N, Suzuki K, Kinoshita K, Nagasaki M, Yamamoto M.

Pharmacogenomics J. 2019 Apr;19(2):136-146. doi: 10.1038/s41397-017-0010-4. Epub 2018 Jan 19.

PMID:
29352165
50.

Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis.

Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fujimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RG, Chinoy H, Rothwell S, Lamb JA, Vencovský J, Mann H, Ohmura K, Myouzen K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawasumi H, Iwasaki Y, Kajiyama H, Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Mimura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, Yamamoto K.

Ann Rheum Dis. 2018 Apr;77(4):602-611. doi: 10.1136/annrheumdis-2017-212149. Epub 2018 Jan 13.

PMID:
29331962

Supplemental Content

Loading ...
Support Center